The share prices of several notable marijuana stocks are slumping on a new warning about cannabidiol (CBD) from the U.S. Food and Drug Administration (FDA).
Yesterday the health industry regulator issued a new “consumer update” regarding CBD, the nonpsychoactive ingredient in cannabis that proponents say has medicinal properties.
The FDA sounded a fairly alarming note about the substance. It pointed out that using CBD can result in…
liver injury, cause significant side effects if used in conjunction with other drugs, and cause drowsiness and mood swings. The regulator emphasized that these effects could occur before a user is aware of them.
Among certain consumers, CBD is a popular ingredient in various types of products such as food, beverages, and ointments. Manufacturers frequently claim that consuming the substance can treat a range of ailments.
The FDA said in its update that “there is very limited available information about CBD, including about its effects on the body.”
“The FDA recognizes the significant public interest in cannabis and cannabis-derived compounds, particularly CBD,” it added. “However, there are many unanswered questions about the science, safety, and quality of products containing CBD.”
Among these are concerns about sustained regular use, its effect on the developing brains of children, and possible male reproductive toxicity.
The regulator said that it is currently laboring to enhance its knowledge of the substance.
To date, the FDA has approved only a single CBD-based drug, Epidiolex from U.K.-based GW Pharmaceuticals (NASDAQ:GWPH). While Epidiolex has been a star product for GW Pharmaceuticals, it is quite limited since it’s used to treat two uncommon forms of epilepsy.
Continue reading at THE MOTLEY FOOL